Crusted Scabies and Pemphigoid: Ivermectin Plus Dupilumab
When a blistering autoimmune disease and a heavy mite infestation appear in the same elderly patient, the crusted scabies component is easy to miss. Here, a brief course of methylprednisolone followed by dupilumab resolved the blisters in one week, and three weekly oral ivermectin doses plus debridement and sulfur cleared the crusts by day 30.
Why crusted scabies matters in immunosuppressed elderly patients
Clinicians also know the condition as Norwegian scabies. Both names cover one severe cutaneous infestation by Sarcoptes scabiei var. hominis, in which the mite population expands into thick hyperkeratotic plaques rather than the few scattered burrows of the ordinary form. What changes is the host, not the parasite. An immunocompetent adult ends up with a handful of itchy papules, while a host whose cellular immunity has faded ends up with a dense bark-like crust. Crusted scabies is therefore a description of the response, never a separate species of mite.
Risk sits on two host factors. Age and any therapy that blunts T-cell responses allow a small infestation to escalate, and systemic corticosteroids are the trigger named most often when this complication is reported. A blistering autoimmune disease supplies nearly ideal conditions, because the dermatosis breaks the epidermal barrier and its usual first-line treatment removes the defense that keeps mite numbers contained.
The consequence is not confined to one patient. A heavy mite load plus easy spread means a missed diagnosis on a ward or in a nursing home turns a single admission into an outbreak. Spotting the picture early, and controlling the autoimmune and parasitic problems at the same time, is the practical goal, and the case below shows how that looked in practice.
Case profile and baseline findings at admission
A 76-year-old man was seen in September 2025 with generalized erythema, tense bullae and severe pruritus that had been present for 5 months. Hypertension, a post-cerebral-infarction state with bedridden status, aphasia and malnutrition filled out the rest of his history, and together they left very little room for aggressive therapy.
The preceding five months had already taken a wrong turn. Erythema and blisters began locally and the family read them as decubitus ulcers, herbal preparations were tried without success, and hyperkeratotic crusting on both hands kept advancing. An outside assessment 2 months before presentation suspected pemphigoid with eczematous change and began systemic corticosteroids with immunoglobulin. Truncal lesions responded partly while the upper limbs deteriorated. Scabies was then suspected and a course of sulfur ointment was given without benefit, a pulmonary infection appeared during that stay, and he was referred after relapsing over roughly 50 percent of his body surface area 3 days after discharge.
Vital signs were stable on arrival. The skin carried widespread erythema and tense bullae across the head, face, torso and lower limbs, along with dry bark-like hyperkeratotic crusts on the hands. Hematoxylin and eosin sections held a subepidermal blister cavity packed with neutrophils, superficial dermal edema, mucoid degeneration and a mixed lymphocytic and neutrophilic infiltrate. Periodic acid-Schiff staining showed a fragmented basement membrane zone with a weakly positive line at the blister base, type IV collagen stained positive on immunohistochemistry, and Gram staining detected no bacteria.
Direct immunofluorescence found linear C3 and IgG deposits along the basement membrane zone with negative IgM, IgA and fibrinogen, the expected pemphigoid pattern. Serology confirmed the autoimmune half: anti-BP230 measured 77.93 U/mL against a reference below 20, anti-BP180 sat above 400 U/mL against the same reference, and anti-desmoglein 1 with anti-desmoglein 3 stayed negative, which excluded pemphigus vulgaris. Microscopy of a skin sample revealed the mite, so crusted scabies joined bullous pemphigoid in the final diagnosis.
Timepoint | Event | Significance |
5 months before admission | Localized erythema and blisters appeared | Read as decubitus ulcers and treated with herbal preparations |
2 months before admission | Pemphigoid suspected at an outside assessment | Systemic corticosteroids plus immunoglobulin started |
Same period | Hand crusting kept progressing | Truncal lesions only partially controlled |
Later in that admission | Scabies suspected and sulfur ointment applied | No effect, and a pulmonary infection developed |
3 days after discharge | Relapse over about 50 percent of body surface | Referral for combined dermatology and parasitology assessment |
On admission | Tense bullae plus bark-like crusts on both hands | Mite seen on microscopy, so the dual diagnosis was confirmed |
Start of therapy | Methylprednisolone 40 mg per day | Bridge treatment until the biologic took effect |
1 week | Blister resolution with fading erythema | Rapid response after the dupilumab loading dose |
30 days | Significant resolution of truncal and hand lesions | Combined regimen judged effective |
Late December 2025 | Death from pulmonary infection | No skin recurrence before death |
The mutually reinforcing cycle between pemphigoid and crusted scabies
The two conditions keep each other alive through four routes, and understanding that loop explains why single-track treatment disappoints.
Pemphigoid brings intense pruritus and widespread skin damage, and a broken epidermal barrier lets mites invade and multiply. Standard pemphigoid treatment then adds systemic corticosteroids and immunosuppressants, which blunt cellular immunity and let a small mite population expand into the crusted form. The Th2-dominant immune profile of pemphigoid also tilts the response away from the Th1 arm that parasitic control depends on. Finally, burrowing mites and the scratching they provoke can open fresh blisters through the Koebner phenomenon in active disease, and infestation may push anti-basement-membrane-zone antibody levels higher.
In this patient the crusted form followed corticosteroid treatment given elsewhere, so immunosuppression from the disease and from the drug looks like the precipitating factor rather than the mite acting first. That order of events carries a planning consequence: once an elderly bedridden patient starts steroids for a bullous disease, mite surveillance stops being optional.
Diagnostic traps that delay crusted scabies diagnosis
Thick scales and crusts look like the eczematized or secondary lesions of pemphigoid, and itching is written off as disease activity. Bullous scabies muddies the picture further by mimicking pemphigoid clinically and histologically. Serology for anti-BP180 and anti-BP230 settles the autoimmune question, microscopy or dermoscopy settles the mite question, and a mixed picture requires both answers.
Both traps appeared here. The crusts were first interpreted as pemphigoid-related eczema and a mite was confirmed only afterwards under the microscope. A workable screening rule follows: in an immunosuppressed patient with a bullous disease, atypical crusted lesions or a poor response to adequate steroid therapy, a mite search is mandatory until it returns negative.
Disease | Cause | Lesion | Key evidence |
Pemphigoid with crusted scabies | Autoimmunity plus mite infestation | Tense bullae with negative Nikolsky sign and hyperkeratotic scales on the hands | Anti-BP180 and anti-BP230 antibodies positive and mites on microscopy |
Bullous scabies | Mite infestation alone | Tense bullae with negative Nikolsky sign | Mites found and anti-BP180 and anti-BP230 antibodies negative |
Pemphigus vulgaris | Autoimmunity | Flaccid bullae with positive Nikolsky sign | Anti-desmoglein 1 and anti-desmoglein 3 antibodies positive |
Treatment sequence with dupilumab and oral ivermectin
One constraint shaped the whole regimen. The patient had already developed a pulmonary infection while on glucocorticoids elsewhere, so a second broad immunosuppressive exposure was unacceptable, and the plan therefore attacked the infestation and the dermatosis together from the first day.
Methylprednisolone began at 40 mg per day. Dupilumab joined once the pemphigoid diagnosis was confirmed, given as a 600 mg loading dose and then 300 mg every 2 weeks. Blisters resolved and erythema faded within 1 week, after which glucocorticoids were tapered and stopped. The speed deserves emphasis, since it beats the median of about 2 months described for dupilumab used alone, most likely because the biologic ran alongside a steroid bridge instead of replacing one later.
On the parasitic side, oral ivermectin was dosed at 12.5 mg weekly for 3 weeks with crust debridement and 10 percent sulfur ointment. Truncal and hand lesions had resolved substantially after 30 days of the combined schedule. Isolation started during the admission because of the contagion risk, clothing went through high-temperature sterilization, the living space was disinfected, and relatives with matching symptoms were diagnosed and isolated elsewhere, which shut down household transmission.
He left hospital in October 2025 after the second dupilumab dose and took the final dose as an outpatient. Follow-up ran until late December 2025, when a pulmonary infection, possibly acquired during the earlier admission, proved fatal. The skin never relapsed before his death.
Agent | Dose and schedule | Target | Observed effect |
Methylprednisolone | 40 mg per day initially | Suppress pemphigoid inflammation | Partial control as a bridge only |
Dupilumab | 600 mg loading dose then 300 mg every 2 weeks | Interleukin-4 and interleukin-13 signaling | Blister resolution within 1 week, steroids then stopped |
Oral ivermectin | 12.5 mg per week for 3 weeks | Mite clearance | Truncal and hand lesions largely resolved by 30 days |
Sulfur ointment 10 percent | Topical application with mechanical debridement | Reduce surface mite burden and crust mass | Used throughout the acaricidal phase |
Isolation and fomite control | Single room, high-temperature laundering, environment disinfection | Interrupt transmission | No further spread documented in the ward |
Spectrum boundaries: why albendazole cannot substitute for an acaricide
Albendazole sits in the benzimidazole class, and its antiparasitic effect comes from binding beta-tubulin in nematode cells, which halts microtubule assembly and interrupts glucose transport. Benzimidazole products are therefore developed and labeled for nematode indications, from intestinal roundworms through tissue-stage larvae, and the spectrum ends where the nematode ends.
An arthropod causes the infestation described above, not a nematode. Albendazole has no documented mite-clearing effect, and its pharmacokinetic profile targets gut and tissue nematode exposure rather than the keratin layer where Sarcoptes females burrow. Reading a benzimidazole into a mite problem mistakes taxonomic proximity for pharmacological overlap, and the distance between the two is wide, because targets, dosing logic and labeled claims all differ.
A macrocyclic lactone carried the acaricidal work here. Ivermectin paralyzes the mite through glutamate-gated chloride channels, and it was combined with physical removal of the crusts and topical sulfur to cut the burden at the surface. For formulation and quality teams the conclusion is about labeling discipline: a nematode anthelmintic and an acaricide answer separate clinical questions, a mite infestation is not a benzimidazole indication, and spectrum boundaries are better stated plainly than stretched by biology that merely sounds adjacent.
Published experience with scabies and bullous disease occurring together
Earlier reports approach the same collision from different angles. One described a 4-month-old infant with refractory scabies who later developed a bullous dermatosis, which raises the possibility that infestation comes first. Another described an 89-year-old woman with suspected pemphigoid who developed the crusted form after dexamethasone. A series of 10 bullous scabies cases argued that blisters responding poorly to steroids should prompt a mite search. A further report concerned a 57-year-old woman with pemphigus vulgaris who developed the crusted form after immunosuppressive treatment.
Taken together, those reports support a causal suspicion: glucocorticoid and immunosuppressive therapy raise susceptibility to scabies and can push a limited infestation into the crusted form. What earlier authors left untouched was the glucocorticoid problem itself in elderly patients, and that is the gap this case fills by making the biologic the steroid-sparing backbone and the acaricide a parallel obligation.
Patient | Initial diagnosis | What preceded the crusted form | Teaching point |
4-month-old infant | Refractory scabies | Infestation came first | Mite disease can trigger a bullous dermatosis |
89-year-old woman | Suspected pemphigoid | Dexamethasone therapy | Steroids can unlock the crusted form |
10 cases of bullous scabies | Blisters with poor steroid response | Mite infestation | A failed steroid trial should trigger a mite search |
57-year-old woman | Pemphigus vulgaris | Immunosuppressive therapy | Any cellular immunosuppression raises the risk |
Practical decisions for clinicians managing Norwegian scabies
- Order a mite search whenever a steroid-treated bullous eruption comes with crusted hands, an unusual distribution or a weak response to an adequate dose.
- Run antiparasitic and anti-inflammatory treatment on one clock rather than letting the dermatosis resolve first.
- Choose a steroid-sparing biologic as the maintenance backbone when age, immobility and prior infection make cumulative steroid exposure hazardous.
- Shorten the steroid bridge and taper it the moment blistering stops instead of extending it out of habit.
- Pair oral acaricidal treatment with debridement and a topical agent, since crust mass shields mites from any route used alone.
- Start isolation, high-temperature laundering and environmental disinfection on the day the diagnosis is suspected rather than after a second confirmation.
- Check household members and close contacts for symptoms, because reinfestation from home is the usual cause of relapse after correct treatment.
- Record the sequence of drugs with dates and doses so the next clinician can tell which agent did what.
Limitations of a single case experience
This is one patient without a comparator arm, so nothing here ranks dupilumab plus ivermectin above any other regimen. Blister clearance inside 1 week describes a single course rather than an effect size, especially because a steroid bridge was running at the same time and attribution to the biologic alone is not safe.
Ivermectin was given as a fixed weekly dose instead of a weight-based schedule, so no conclusion about the best approach in cachectic or malnourished patients can be drawn. The fatal pulmonary infection was documented without detailed microbiology, leaving its origin unclear and blocking any analysis of infection risk attributable to the regimen. Follow-up also ended with the death in late December 2025, so long-term recurrence risk after apparent clearance stays unknown.
Bottom line
A blistering autoimmune disease and a heavy mite burden in one elderly patient create a double problem: treatment for the dermatosis supplies the immunosuppression that lets mites multiply, and the crusts conceal the mite from clinicians watching for blisters. Here a brief methylprednisolone induction, a dupilumab backbone and three weekly oral ivermectin doses with debridement and topical sulfur cleared the skin with no recurrence before death, and none of it would have started without the mite search that earlier assessments skipped.
FAQ
What is crusted scabies?
Crusted scabies is the severe form of infestation by the scabies mite, in which thick hyperkeratotic plaques and crusts form instead of the small burrows of ordinary scabies. It appears mostly in elderly, debilitated or immunosuppressed people, carries an extremely heavy mite load and is far more contagious than the ordinary form. The label describes how the host responds to the mite, not a separate species of mite.
How does crusted scabies differ from ordinary scabies?
Ordinary scabies produces intense itching with a few papules and visible burrows and usually carries a small mite population. Crusted scabies produces widespread scaling and thick bark-like crusts, often with less itching than expected, and the mite count can be enormous because cellular immunity fails to contain proliferation. That difference drives everything else: higher contagion, harder diagnosis, and a need for repeated oral acaricidal treatment alongside topical care.
Why do corticosteroids make crusted scabies worse?
Corticosteroids suppress the cellular immune response that normally keeps mite numbers in check. When a patient with a limited infestation starts systemic steroid therapy, the mites multiply unchecked and the ordinary form can convert into the crusted form. In this case the crusted lesions appeared only after corticosteroid treatment elsewhere, which is why the management plan deliberately kept steroid exposure short and moved quickly to a steroid-sparing biologic.
Can crusted scabies be mistaken for bullous pemphigoid?
Yes, and the confusion runs in both directions. Hyperkeratotic crusts can look like the eczematized lesions of pemphigoid, itching is easily credited to the autoimmune disease, and bullous scabies can mimic pemphigoid clinically and histologically. Serology for anti-BP180 and anti-BP230 antibodies confirms the autoimmune side while microscopy confirms the mite, so the two tests answer two different questions and both are needed when the picture is mixed.
Is oral ivermectin enough to clear crusted scabies?
Oral therapy alone is usually not sufficient in the crusted form because the thick crust mass shields mites from any single route of delivery. The regimen here combined a weekly oral dose with mechanical debridement of the crusts and a topical sulfur preparation, and clearance was judged at 30 days. The combination matters more than the individual agent, because debridement physically reduces the burden that the drug then has to reach.
What dose of ivermectin was used in this case?
The patient received 12.5 mg of oral ivermectin once per week for 3 consecutive weeks, alongside debridement and 10 percent sulfur ointment. That is a fixed dose, not a weight-adjusted schedule, and it was given in parallel with dupilumab rather than as monotherapy. The case report does not compare this schedule against any alternative, so the number should be read as a description of one course rather than as a recommended protocol.
Does albendazole work against scabies mites?
No established mite-clearing activity is documented for albendazole. Benzimidazoles such as albendazole act by binding beta-tubulin in nematodes and blocking microtubule assembly, and their labeled spectrum sits inside nematode indications. The scabies mite is an arthropod with different drug targets, so a benzimidazole anthelmintic cannot be substituted for an acaricide when the diagnosis is a mite infestation rather than a roundworm infection.
How long does treatment take before the crusts resolve?
In this case significant resolution of the truncal and hand lesions was recorded after 30 days of combined therapy, while the blistering component responded within 1 week of adding the biologic. The two timelines move at different speeds because they answer different problems: inflammation fades quickly once the interleukin-4 and interleukin-13 pathway is blocked, whereas crusts and damaged skin need time and repeated debridement to clear.
Is dupilumab necessary in every patient with Norwegian scabies?
No. Dupilumab was chosen here because the coexisting bullous pemphigoid needed systemic control and the patient could not tolerate prolonged corticosteroids after an earlier pulmonary infection. In a patient with the infestation alone there is no bullous disease to suppress, so the acaricidal and hygiene measures carry the case by themselves. The biologic addresses the autoimmune half of a dual diagnosis, not the mite.
What infection control steps are required?
Isolation during hospitalization, high-temperature laundering of clothing and disinfection of the living environment are the core measures, and they should start when the diagnosis is suspected rather than when it is confirmed twice. Household members and close contacts need screening, because reinfestation from the home is the most common reason a correctly treated patient relapses. In this case relatives with similar symptoms were diagnosed and isolated separately, which closed that loop.
What is the prognosis for an elderly bedridden patient with this combination?
Guarded, and driven more by comorbidity than by the skin itself. The skin lesions in this case cleared without recurrence, yet the patient died of a pulmonary infection months later, a reminder that bedridden elderly patients with multiple underlying diseases carry competing risks. Successful skin control removes one source of sepsis and barrier failure, but it does not change the underlying frailty that made the presentation dangerous in the first place.
What are the limits of this single case report?
It reports one patient with no control group and no statistical comparison, so it can suggest a strategy but cannot rank it against alternatives. Several details remain unresolved, including the microbiological origin of the fatal infection and any long-term recurrence risk after apparent clearance. The value of the report is in the sequence it documents, namely concurrent antiparasitic and anti-inflammatory treatment under close monitoring, rather than in any dose that should be copied unchanged.